Activation of protein kinase C (PKC) is cardioprotective, but the mechanism(s) by which PKC mediates protection is not fully understood. Inasmuch as PKC has been well documented to modulate sarcoplasmic reticulum (SR) Ca 2ϩ and because altered SR Ca 2ϩ handling during ischemia is involved in cardioprotection, we examined the role of PKC-mediated alterations of SR Ca 2ϩ in cardioprotection. Using isolated adult rat ventricular myocytes, we found that addition of 1,2-dioctanoyl-sn-glycerol (DOG), to activate PKC under conditions that reduced myocyte death associated with simulated ischemia and reperfusion, also reduced SR Ca 2ϩ . Cell death was 57.9 Ϯ 2.9% and 47.3 Ϯ 1.8% in untreated and DOG-treated myocytes, respectively (P Ͻ 0.05). Using fura 2 fluorescence to monitor Ca 2ϩ transients and caffeine-releasable SR Ca 2ϩ , we examined the effect of DOG on SR Ca 2ϩ . Caffeine-releasable SR Ca 2ϩ was significantly reduced (by ϳ65%) after 10 min of DOG treatment compared with untreated myocytes (P Ͻ 0.05). From our examination of the mechanism by which PKC alters SR Ca 2ϩ , we present the novel finding that DOG treatment reduced the phosphorylation of phospholamban (PLB) at Ser 16 . This effect is mediated by PKC-⑀, because a PKC-⑀-selective inhibitory peptide blocked the DOG-mediated decrease in phosphorylation of PLB and abolished the DOG-induced reduction in caffeine-releasable SR Ca 2ϩ . Using immunoprecipitation, we further demonstrated that DOG increased the association between protein phosphatase 1 and PLB. These data suggest that activated PKC-⑀ reduces SR Ca 2ϩ content through PLB dephosphorylation and that reduced SR Ca 2ϩ may be important in cardioprotection.
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calcium; protein kinase C-⑀; 1,2-dioctanoyl-sn-glycerol; protein phosphatase 1 ISCHEMIC PRECONDITIONING (PC) refers to the phenomenon whereby intermittent brief episodes of ischemia and reperfusion reduce myocardial infarct size and contractile dysfunction induced by a subsequent sustained episode of ischemia. The signaling pathways involved in PC have been investigated intensively, and there is considerable support for the role of protein kinase C (PKC) in mediating PC (9, 24, 33, 38) . However, the precise targets of PKC that mediate protection are poorly understood. It has been suggested that PKC mediates PC by modulating the mitochondrial ATP-sensitive K ϩ channel (37) . PKC has also been reported to bind to or modulate the phosphorylation of several mitochondrial proteins (2, 3) . Additional targets of PKC are likely involved in mediating cardioprotection. PKC has been shown to alter Ca 2ϩ transients, contractility, and sarcoplasmic reticulum (SR) Ca 2ϩ handling (6, 18, 29, 31, 35, 36) ; although there is some controversy, most studies suggest that activation of PKC decreases contractility, attenuates Ca 2ϩ transients, and decreases SR Ca 2ϩ content (6, 18, 29, 35, 36 (8, 30, 39, 41) .
SR Ca 2ϩ handling plays a significant role in the regulation of cardiac contractility. Ca 2ϩ uptake into the SR is mediated by the sarco(endo)plasmic reticulum Ca 2ϩ -ATPase isoform 2 (SERCA2), which is regulated by phospholamban (PLB). PLB inhibits SERCA2, leading to a reduced rate of Ca 2ϩ uptake into the SR and a slower rate of relaxation. Phosphorylation of PLB causes dissociation of PLB from SERCA2, allowing faster rates of SR Ca 2ϩ uptake and relaxation and enhanced contractility through increased SR Ca 2ϩ loading. SR Ca 2ϩ release is regulated by the SR Ca 2ϩ release channel, which binds ryanodine and is therefore referred to as the ryanodine receptor. The mechanisms by which PKC alters SR Ca 2ϩ are not well understood.
The aim of the present study was to examine the role of PKC modulation of SR Ca 2ϩ in cardioprotection. Using adult rat cardiomyocytes, we found that addition of the PKC activator 1,2-dioctanoyl-sn-glycerol (DOG), under conditions that were cardioprotective, resulted in a decrease in SR Ca 2ϩ . We further examined the mechanism by which PKC might alter SR Ca 2ϩ and found that activation of PKC resulted in a decrease in the phosphorylation of PLB and an increase in the association between PLB and protein phosphatase (PP) 1.
MATERIALS AND METHODS
Isolation of cardiomyocytes. Ventricular myocytes were isolated from male Sprague-Dawley rats (8 -10 wk, 250 -300 g) by collagenase perfusion as described previously (16 Simulated ischemia model. To examine whether DOG is protective in isolated adult rat cardiomyocytes, we subjected myocytes to sim-ulated ischemia by pelleting the myocytes as described previously (1) . Freshly isolated myocytes were divided into two experimental groups and treated with or without 3 M DOG for 10 min, washed twice, and then pelleted and covered with mineral oil and incubated at 37°C for up to 4 h. Cell viability was assessed with trypan blue as a function of time as described elsewhere (1) . Microscopic examination at ϫ40 magnification was used to determine morphology (rod-shaped myocytes) and trypan blue staining.
Ca
2ϩ measurements in isolated rat myocytes. Freshly isolated myocytes were placed on laminin-coated glass coverslips and allowed to attach for 30 min before they were loaded with fura 2-AM (Molecular Probes). Myocytes on coverslips were placed on the stage of a Nikon microscope connected to a Photon Technology International spectrofluorometer and superfused with modified Hanks' balanced salt solution. All fura-2 experiments were conducted at room temperature. Myocytes were treated with or without 3 M DOG for 10 min and field stimulated at 0.5 Hz. For the chelerythrine protocol, myocytes were treated with 2 M chelerythrine for 1 min and then with 3 M DOG ϩ 2 M chelerythrine for 9 min. Studies were also done by using ⑀V1-2 peptide (amino acids 14 -21 of PKC-⑀), a selective PKC-⑀ inhibitor, which was synthesized at the Stanford Protein and Nucleic Acid Facility (Stanford, CA). The myocytes were treated with 1 M ⑀V1-2 peptide or 1 M control peptide for 20 min, and DOG was added for 10 min. Field stimulation was stopped just before caffeine (20 mmol/l) addition, and caffeine-releasable Ca Western blot analysis. Myocytes were mixed with ice-cold lysis buffer containing (in mmol/l) 75 NaCl, 20 HEPES (pH 7.4), 2.5 MgCl 2, 0.1 EDTA, 0.5 DTT, 0.1 Na3VO4, 1 NaF, and 20 glycerophosphate, with 0.1% Triton X-100 and protease inhibitors, homogenized, and snap frozen and stored in liquid nitrogen until Western blots were run. Proteins were separated by 14% SDS-PAGE and blotted onto nitrocellulose membranes (Invitrogen). Membranes were probed with the following primary antibodies: PLB (catalog no. MA3-922, Affinity Bioreagents; diluted 1:2,000) and Ser 16 -phosphorylated PLB (phospho-Ser 16 PLB; RDI-PPHOSLAMBabR, Research Diagnostics; diluted 1:700). We found two immunoreactive bands at ϳ25 kDa, the molecular mass for the phospho-PLB pentamer. However, we confirmed in two ways that the upper band was nonspecific: 1) If we reprobed with total-PLB antibody after stripping was completed, the upper band was not recognized by total (nonphosphorylated) PLB antibody. 2) If we boiled the sample to convert the PLB pentamer to a monomer, the lower 25-kDa band was converted to the monomer band (5 kDa) detected with the phosphorylated PLB antibody, but the nonspecific upper 25-kDa band remained. For clarity, we show only the lower 25-kDa band, which was shown to be specific for PLB. The optical density of immunoreactive bands was quantified by using NIH Image.
Immunoprecipitation analysis. Lysates from myocytes were incubated with 2 g of PP-1 antibody (Cell Signaling Technology) in a buffer containing (in mmol/l) 150 NaCl, 20 HEPES (pH 7.4), and 1 EDTA, with 0.1% Nonidet P-40, for 2 h at 4°C. Protein G-agarose (50 l) was added, and the solutions were incubated at 4°C overnight. Pellets were rinsed four times, resuspended with sample buffer, boiled, and centrifuged, and the supernatants were subjected to immunoblotting (PLB mouse monoclonal, Affinity Bioreagents).
Statistical analysis. Values are means Ϯ SE. For comparison between two groups, a Student's t-test was used. P Ͻ 0.05 was considered statistically significant.
RESULTS

Simulated ischemia study.
Previous studies in in vivo and perfused heart models showed that the PKC activators result in cardioprotection that is comparable to the protective effect of ischemic PC (9, 38) . Studies have also demonstrated that the protection afforded by a PKC activator can be blocked by a PKC peptide inhibitor (⑀V1-2) (23) . In this study, we demonstrate reduced cell death in DOG-treated myocytes after simulated ischemia. Before simulated ischemia, there was no difference in cell viability between untreated control and DOG (3 M)-treated myocytes: 24.8 Ϯ 3.4% and 24.0 Ϯ 2.1%, respectively (Fig. 1) . With simulated ischemia, cell death was increased in untreated control myocytes compared with myocytes treated with DOG. After 4 h of simulated ischemia, 70.7 Ϯ 2.0% of control myocytes and 53.3 Ϯ 1.7% of DOGtreated myocytes stained with trypan blue. The oxygenated control group retained a predominantly rod-shaped morphology and excluded trypan blue for the 4-h duration of the experimental protocol (Fig. 1, dashed line) . These results indicate that 3 M DOG can protect isolated myocytes. 16 phosphorylated phospholamban (Phos-PLB) and an antibody that recognizes total PLB were used. DOG treatment for 10 min reduced phosphorylation of PLB at Ser 16 . Bottom: graphic representation of Western blot data. Values are means Ϯ SE; n ϭ 6 -7 rats. *Significantly different from control (P Ͻ 0.05). content. Figure 2 shows caffeine-releasable SR Ca 2ϩ in untreated myocytes, in DOG-treated myocytes, and in myocytes treated with DOG ϩ the PKC inhibitor chelerythrine. DOG treatment decreased caffeine-releasable SR Ca 2ϩ (259 Ϯ 45 and 448 Ϯ 57 nmol/l in DOG-treated and control myocytes, respectively, P Ͻ 0.05), and chelerythrine blocked this DOGinduced reduction in SR Ca 2ϩ content (259 Ϯ 45 and 462 Ϯ 72 nmol/l in DOG-and DOG ϩ chelerythrine-treated myocytes, respectively, P Ͻ 0.05).
[ ] i transient in DOG-treated myocytes was reduced (Fig.  3A) , we examined the rate of Ca 2ϩ uptake and release in stimulated DOG-treated myocytes. In DOG-treated myocytes, the half-decay time of the Ca 2ϩ transient was prolonged compared with untreated myocytes (Fig. 3B) : 172 Ϯ 25 and 213 Ϯ 25 ms at 0 and 10 min, respectively (P Ͻ 0.05). There was no difference in time to peak Ca 2ϩ (Fig. 3C) . Because the SR removes 92% of total activator Ca 2ϩ in rat ventricular myocytes, the half-decay time can be used as an index of SR Ca 2ϩ uptake (26) . Therefore, the prolongation of the decay in the Ca 2ϩ transient suggests that SR Ca 2ϩ uptake is decreased by PKC activation.
Dephosphorylation at Ser 16 on PLB. Ca 2ϩ uptake is regulated by SERCA2 and PLB. Dephosphorylated PLB is an inhibitor of SERCA2, and phosphorylation of PLB relieves its inhibitory effects on SERCA2 (10, 21) . We therefore examined whether DOG alters phosphorylation at Ser 16 of PLB. Myocytes treated with DOG for 10 min showed a marked dephosphorylation of PLB compared with control myocytes (P Ͻ 0.05; Fig. 4) . No difference in total PLB protein levels was detected between control and DOG-treated myocytes. Figure 5 shows a time course of PLB dephosphorylation at Ser 16 after DOG treatment.
PP-1 and PLB. The DOG-dependent dephosphorylation of PLB is consistent with the DOG-induced reduction in SR Ca 2ϩ content. Dephosphorylation of PLB is reported to be primarily mediated by PP-1 (25) . To investigate whether PP-1 might be involved in PKC-dependent dephosphorylation of PLB, myocytes were treated with and without DOG for 10 min, extracted in lysis buffer, and immunoprecipitated to determine whether DOG increased the association between PP-1 and PLB. DOG treatment resulted in a significant increase in the association of PP-1 and PLB as determined by immunoprecipitation with PP-1 followed by PLB immunoblotting (Fig. 6) . We also tested whether PKC-⑀ coimmunoprecipitated with PP-1, but we found no association in the presence or absence of DOG (data not shown).
PKC-⑀ regulates phosphorylation of PLB. Inasmuch as PKC-⑀ has been reported to mediate cardioprotection, we were interested in examining the role of PKC-⑀ in the dephosphorylation of PLB. We tested whether a PKC-⑀ isozyme-selective inhibitory peptide, ⑀V1-2 (20), would block the DOG-mediated decrease in PLB dephosphorylation. This eight-amino acid peptide, derived from the V1 region of PKC-⑀, inhibits activation-induced translocation and function of PKC-⑀ in cardiomyocytes (20) . Myocytes were treated for 20 min with 1 M ⑀V1-2 peptide and then incubated with or without DOG for 10 min. The carrier peptide alone (1 M) also was used as a negative control. Addition of DOG in the presence of an inactive control peptide resulted in a significant decrease in phosphorylation of PLB (Fig. 7) , similar to that observed in Fig. 4 . Addition of DOG in the presence of 1 M ⑀V1-2 resulted in no change in phosphorylation of PLB. Interestingly, addition of ⑀V1-2 in the absence of DOG caused a slight but significant increase in phosphorylation of PLB/total PLB, suggesting a degree of basal activation of PKC-⑀ in normal cardiomyocytes.
Effect of PKC-⑀ on caffeine-releasable SR Ca 2ϩ and SR function. We further tested whether the PKC-⑀-selective inhibitor peptide would affect the DOG-mediated decrease in caffeine-releasable SR Ca 2ϩ described in Fig. 2 . The PKC-⑀ inhibitor blocked the DOG-induced reduction in SR Ca 2ϩ content: 188 Ϯ 31 and 324 Ϯ 44 nmol/l with DOG and PKC-⑀ inhibitor ϩ DOG, respectively (P Ͻ 0.01; Fig. 8A ).
We also examined whether the PKC-⑀ inhibitor peptide would block the DOG-induced prolongation of the decay of the Ca 2ϩ transients (Fig. 3) . Addition of the PKC-⑀ inhibitor blocked the DOG-induced prolongation of the half-decay time of the Ca 2ϩ transient (Fig. 8B) .
DISCUSSION
PKC and cardioprotection.
A role for PKC in cardioprotection has been well established (9, 13, 17, 19, 24, 27, 38, 40) . PC has been shown to result in the translocation of PKC, specif- ically PKC-⑀, to membrane fractions, and inhibitors of PKC have been shown to block the protection afforded by PC (38) . Furthermore, mice with moderate cardiac-specific overexpression of PKC-⑀ have been shown to be protected against ischemia-reperfusion injury compared with wild-type littermates (11) . Similarly, hearts of mice overexpressing a peptide that enhances translocation and function of PKC-⑀ or pigs treated in vivo with this peptide by a single intracoronary infusion before or early during the ischemic period exhibit a Ͼ60% cardioprotection (13, 19) . Despite the well-established role for PKC-⑀ in cardioprotection, the target mechanisms by which PKC mediates protection are just beginning to be elucidated. PKC has been shown to phosphorylate troponin I (5), and PKC has been suggested to activate the mitochondrial ATP-sensitive K ϩ channel (37) . PKC-⑀ has also been reported to interact with components of the mitochondrial permeability transition pore (2) and to mediate phorbol ester-induced phosphorylation of connexin-43 (12) . PKC-⑀ also forms a complex with Lck (32) or MAPK, resulting in phosphorylation of Bad (3) .
PKC and SR Ca 2ϩ content. PKC activation has also been reported to modulate cytosolic Ca 2ϩ , contractility, and SR Ca 2ϩ (6, 18, 29, 31, 35, 36) . Given the importance of cytosolic and SR Ca 2ϩ in ischemia-reperfusion injury, we investigated whether SR Ca 2ϩ -handling proteins might be additional targets of PKC. Consistent with the majority of data (6, 18, 29, 35, 36) , we found that addition of DOG results in a decrease in SR Ca 2ϩ content (ϳ65% decrease), which was abolished by addition of the PKC inhibitor chelerythrine or the selective PKC-⑀ inhibitor peptide. A decrease in SR Ca 2ϩ would be expected to be cardioprotective, inasmuch as it would decrease SR Ca 2ϩ cycling, reduce a potential trigger for arrhythmias, and potentially attenuate the rise in cytosolic Ca 2ϩ during ischemia and reperfusion (8, 39) . Previous data suggested that modulation of SR Ca 2ϩ is important in cardioprotection (42) . In addition, studies have suggested that SR Ca 2ϩ cycling is an important determinant of survival of ischemic or metabolically inhibited myocytes (14, 22) . Cave and Garlick (7) showed that addition of ryanodine and cyclopiazonic acid does not block the protection afforded by PC and concluded that a "functional" SR is not required for PC. However, these data do not rule out the hypothesis that reduced SR Ca 2ϩ content is protective, inasmuch as ryanodine and cyclopiazonic acid will reduce SR Ca 2ϩ . PKC and PLB. Activation of PKC has been reported to reduce SR Ca 2ϩ ; however, the mechanism by which PKC alters SR Ca 2ϩ content is not established. Although PKC can phosphorylate PLB in vitro, activation of PKC does not result in an increase of 32 P incorporation into PLB in vivo under conditions where adrenergic receptors were inhibited (15) . We found that DOG decreased phosphorylation of PLB at Ser 16 by Ͼ80% (Figs. 4 and 5) . The effect of DOG was rapid, because 1 min of treatment was sufficient to reduce phosphorylation of PLB. We further demonstrated that the effect of DOG was mediated by PKC-⑀, because an isoform-specific inhibitor of PKC-⑀ blocked the DOG-dependent decrease in phosphorylation of PLB. In addition, DOG enhanced the interaction of PP-1 with PLB, providing additional information regarding the mechanism by which PKC reduces phosphorylation of PLB. PLB is primarily dephosphorylated by the action of PP-1 and PP-2a (25) , and PP-1 is regulated by PP inhibitor-1, which is subject to protein kinase A regulation through phosphorylation at Thr 35 (28) . Interestingly PKC-␣ has recently been shown to influence binding of PP inhibitor-1 to PP-1 (4).
In conclusion, the present data have shown that activation of PKC under conditions that lead to cardioprotection reduces SR Ca 2ϩ loading by a mechanism involving PKC-⑀-mediated dephosphorylation of PLB. Activation of DOG is also shown to enhance binding of PP-1 to PLB, thereby resulting in decreased phosphorylation of PLB, which in turn leads to a decrease in SR Ca 2ϩ content. A decrease in SR Ca 2ϩ at the start of ischemia could lead to less SR Ca 2ϩ cycling and could attenuate the rise in cytosolic Ca 2ϩ during ischemia and reperfusion, which would be cardioprotective (34) . A decrease in SR Ca 2ϩ cycling would reduce the consumption of ATP; interestingly, a reduction in ATP consumption during ischemia has been shown in hearts with cardiac-specific overexpression of PKC-⑀ (11) . SR Ca 2ϩ is also important in the development of arrhythmias, and activation of PKC-⑀ has been reported to have antiarrhythmic efficacy (19) . These findings lend support to the concept that modulation of SR function might be a new important cardioprotective strategy.
